Investing.com -- Piper Sandler downgraded Accolade Inc (NASDAQ:ACCD) to Neutral from Overweight and cut its price target to $7.03 per share, aligning with the proposed acquisition price in the company's pending sale to Transcarent.
Accolade agreed to be acquired by Transcarent, a healthcare navigation firm, for $7.03 per share in cash, a 110% premium to its Jan. 7 closing price.
Shareholders are set to vote on the deal at a special meeting on March 27, with closing expected in the second quarter, pending approval.
“We believe the merger terms are generally favorable and fall in line with several comparable transactions,” analyst at Piper Sandler said.
Piper Sandler noted that Accolade’s fiscal third-quarter 2025 revenue of $105.1 million slightly missed expectations, while adjusted EBITDA of negative $3.8 million came in marginally ahead. The firm also flagged downside risks to consensus estimates for fiscal years 2026-2028, based on management projections.
Despite viewing the sale process as competitive and the terms as generally favorable, Piper Sandler sees limited upside for the stock at this stage.
Related Articles
Piper Sandler downgrades Accolade ahead of shareholder vote
European steel stocks leap on German spending plans
US stocks nearly flat amid trade war worries; euro hits four-month high
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。